Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
NCT03220022Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2018
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib in AIDS-related lymphoma and diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose of Ibrutinib in Combination With Chemotherapy at 21 days and Recommended Phase II Dose of Ibrutinib in Combination With Chemotherapy at 21 days. Started Mar 2018; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
AIDS-related lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03220022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220022.